|
|
 |
|
Viewing report
|
|
|
|
The Pharmacogenomics Outlook
Business Insights, Aug 2000
Pharmaceutical companies are coming under increasing pressure to increase the quality of their products, and optimize and accelerate drug discovery and development.
By identifying differences between patients’ genetic makeup and the effect this has on drug response, pharmacogenomics has the potential to reduce medical costs, improve drug development and therapy and cause a shift from treatment to prevention.
This report coincides with the completion of the map of the genome and the development of new technologies developed following this breakthrough.
Benefiting from a survey of over 50 executives in leading pharmaceutical and pharmacogenomics companies, this report provides a unique insight into the current state and future direction of the pharmacogenomics market over the next ten years. It looks at the key industry drivers, identifies important strategic possibilities and potential for collaboration.
Customers who bought this item also bought
Personalized Medicine - Scientific and Commercial Aspects
Impact of Pharmacogenomics on Public Healthcare Policy: Educating Patients, Payors and Healthcare Providers
Genomics World Markets 2008
DNA Sequencing 2008
Understanding Pharmacogenomics
Proteomics - Technologies, Markets and Companies
Biomarker Technology Platforms for Cancer Diagnoses and Therapies
Cancer, CNS & Cardiovascular Biomarkers: Players, Products and Prospects
Animal Biotechnology - Technologies, Markets and Companies
Personalized Medicine
Molecular Diagnostics - Technologies, Markets and Companies
Companion Diagnostics in Personalized Medicine and Cancer Therapy
|
|
|
|
